Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease
adenosine deaminase deficiency
Adenosine deaminase deficiency (ADA deficiency) is a metabolic disorder that causes immunodeficiency. It is caused by mutations in the ADA gene. It accounts for about 10–15% of all cases of autosomal recessive forms of severe combined immun ...
-
SCID in children and adults.
It is a recombinant
enzyme that is administered weekly by
intramuscular injection.
Elapegademase may interact with
PEGylated drugs.
[
Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018. ]Leadiant Biosciences
Leadiant Biosciences, formerly known as Sigma-Tau Industrie Farmaceutiche Riunite, was founded in 1957 by research chemist Claudio Cavazza.
In 2018 Leadiant Biosciences has come under fire for creating a monopoly for CDCA and unnecessarily inc ...
was awarded a priority review voucher for its development under the pediatric rare diseases program.
References
External links
*
Enzymes used as drugs
Orphan drugs
{{antineoplastic-drug-stub